人类表皮生长因子受体-2在乳腺癌研究中进展  

Current development of human epidermal growth factor receptor-2 in breast cancer research

作　　者：曹明[1] 张帆[1] 

机构地区：[1]皖南医学院弋矶山医院临床病理科,安徽芜湖241001

出　　处：《安徽医药》2015年第12期2263-2267,共5页Anhui Medical and Pharmaceutical Journal

摘　　要：人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)是乳腺癌诊治过程中重要的预后指标和HER-2靶向药物的治疗指标。乳腺癌患者中约30%会出现HER-2的过表达,HER-2检测的目的就是鉴别出那些可以从HER-2靶向治疗中获益的人群。目前靶向治疗药物包括赫赛、拉帕替尼和T-DM1等。这些治疗可以大大提高HER-2阳性浸润性乳腺癌患者的生存期。所以选择适当的检测标准准确判读HER-2状态是乳腺癌患者预后判断以及制定有效治疗方案的先决条件,对乳腺癌的诊疗具有积极的指导作用。Human epidermal growth factor receptor-2（ HER-2） is an important prognostic predictor and key predictor of anti-HER-2therapy of breast cancer. About 30% of breast cancer patients will have HER-2 over expression. The purpose of HER-2 testing is to identify patients who can benefit from the HER-2 targeted therapy. Currently targeted medicines include trastuzumab（ Herceptin）,lapatinib（ Lapatinib）,T-DM1 and the like. These treatments can greatly improve the survival of HER-2-positive invasive breast cancer patients. So choosing the appropriate testing standards and accurate testing of HER-2 status is a prerequisite for making a prognosis and developing effective treatment programs,which is important in clinical practice. The current development of human epidermal growth factor receptor-2 in breast cancer research will be reviewed in this paper.

关 键 词：人类表皮生长因子受体-2(HER-2) 乳腺癌 HER-2检测 

分 类 号：R737.9[医药卫生—肿瘤]